LISA CAVANAUGH, as Personal Representative of the ESTATE OF WILLIAM CAVANAUGH v. STRYKER CORPORATION

CourtDistrict Court of Appeal of Florida
DecidedOctober 7, 2020
Docket19-0523
StatusPublished

This text of LISA CAVANAUGH, as Personal Representative of the ESTATE OF WILLIAM CAVANAUGH v. STRYKER CORPORATION (LISA CAVANAUGH, as Personal Representative of the ESTATE OF WILLIAM CAVANAUGH v. STRYKER CORPORATION) is published on Counsel Stack Legal Research, covering District Court of Appeal of Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LISA CAVANAUGH, as Personal Representative of the ESTATE OF WILLIAM CAVANAUGH v. STRYKER CORPORATION, (Fla. Ct. App. 2020).

Opinion

DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA FOURTH DISTRICT

LISA CAVANAUGH, as the Personal Representative of the ESTATE OF WILLIAM CAVANAUGH, deceased, Appellant,

v.

STRYKER CORPORATION, a foreign corporation, et al., Appellees.

No. 4D19-523

[October 7, 2020]

Appeal from the Circuit Court for the Nineteenth Judicial Circuit, St. Lucie County; George A. Shahood, Senior Judge, and William L. Roby, Judge; L.T. Case No. 562013CA001800 (ME).

Paul M. Silva and Peter J. Somera, Jr. of Somera & Silva, LLP, Boca Raton, Jack Scarola and Michael H. Kugler of Searcy Denney Scarola Barnhart & Shipley, P.A., West Palm Beach, and Andrew A. Harris and Adam Richardson of Burlington & Rockenbach, P.A., West Palm Beach, for appellant.

Hildy M. Saste, William P. Geraghty, Daniel B. Rogers and Jennifer M. McLoone of Shook, Hardy & Bacon, L.L.P., Miami, for appellee.

PER CURIAM.

The Plaintiff, Lisa Cavanaugh, as personal representative of the Estate of William Cavanaugh, appeals a final judgment entered upon a defense verdict in her wrongful death action against Stryker Corporation, a medical device manufacturer (“the manufacturer”). We affirm on all issues raised, addressing only a jury instruction dispute and a juror selection issue. On all other issues we affirm without discussion.

Background

A. Evidence at Trial

In November 2012, Mr. Cavanaugh died while undergoing lung-removal surgery at Lawnwood Regional Medical Center (“the hospital”). The surgical team included a surgeon with the assistance of a registered nurse (“the nurse”).

The manufacturer’s medical device, called the Neptune 2, was used throughout the procedure in order to remove blood and clear the surgical field. The Neptune 2 is a high-flow suction device “intended to collect and dispose of surgical fluid waste.” The device is not intended to be connected or used during passive chest drainage.

During Mr. Cavanaugh’s surgery, the Neptune 2 was connected to suction tubing, which had what is called a Yankauer suction tip attached to it. When the operation was almost finished, the surgeon inserted a chest tube into Mr. Cavanaugh’s chest. The chest tube should have been connected to an Atrium or Pleur-evac, which are devices for passive chest drainage. Instead, the nurse either touched or connected the Yankauer suction tip (and therefore the Neptune 2) to the chest tube, causing Mr. Cavanaugh’s heart to be “sucked . . . over to the other side” of his chest. Mr. Cavanaugh unfortunately died from the immediate and severe blood loss.

Both the surgeon and the nurse testified that they thought standard wall suction was being used for the chest drainage. They both added that they were not aware that the Neptune 2 device was being used. The Plaintiff brought this wrongful death action against various defendants, including the manufacturer. The Plaintiff’s original complaint asserted medical malpractice claims against the hospital and the nurse, but those claims were settled. The claims in the complaint against the manufacturer were for strict liability based on design defects (Count I), strict liability based on failure to warn (Count II), and negligence (Count III).

The manufacturer answered and asserted various defenses, including (1) the learned-intermediary defense, (2) the intervening or superseding cause defense, and (3) a Fabre 1 defense.

At trial, the following evidence was presented about the Neptune 2 device. The Neptune 2 came on the market in 2007. The Neptune 2 had higher suction capabilities than its predecessor, the Neptune 1. Nevertheless, the manufacturer asserted that the Neptune 2 was covered by the clearance that it had obtained from the U.S. Food and Drug Administration (“FDA”) to market the Neptune 1 device.

1 Fabre v. Marin, 623 So. 2d 1182 (Fla. 1993).

2 In June 2012, the manufacturer sent an urgent medical device notification to its customers regarding the instructions for use on the Neptune 2. The Notification stated that “Stryker received one report of a [2010] fatality from a customer in which the Neptune [2] was connected to a passive chest drainage tube post-operatively,” that the current instructions for use did “not specifically warn against connecting the Neptune [2], which is a high vacuum/high flow device, to a passive drainage tube,” and that the instructions for use were being updated with a new warning.

In August 2012, the FDA notified the manufacturer that the Neptune 2 needed its own FDA clearance, as the FDA considered the Neptune 2 to be a potentially adulterated device. The FDA advised the manufacturer that the Neptune 2 “may not be used at this particular time,” but created an exception whereby the device would be allowed to stay in medical use under a certificate of medical necessity.

The next month, Stryker issued a recall notice advising customers that they should no longer use the Neptune 2 unless they had no alternative device to use. The notice stated that, “if you do not have an alternative device to use, you should weigh the risk and benefits of using these devices and if you choose to continue using the either the Neptune Silver or the Neptune 2, you must complete the attached Certificate of Medical Necessity . . . .” An executive of the hospital’s parent company signed a Certificate of Medical Necessity. This certificate was in effect at the time of Mr. Cavanaugh’s surgery.

The warning label affixed to the Neptune 2 at the time of Mr. Cavanaugh’s surgery stated: “DO NOT apply high flow suction in applications that may result in severe injury or death; for example, passive chest drainage,” while still characterizing the device’s suction capabilities as “LOW,” “MEDIUM,” and “HIGH.”

The instructions for use provided a similar warning not to apply high flow suction during procedures such as passive chest drainage, adding that failure to comply may result in serious injury or death. Although the nurse testified that he never read the warnings or instructions for use concerning the Neptune 2, he generally knew that it was not appropriate to apply high suction to a closed drainage system.

The surgeon testified he did not know that the Neptune 2 was only a high-suction device. The surgeon explained that a device without low suction would be inappropriate to use during a lung-removal surgery. Had the surgeon known that the Neptune 2 device was not FDA-approved, or

3 that a previous patient had been severely injured by the device, he would not have allowed the Neptune 2 to be used during the surgery.

The Plaintiff presented expert testimony from a materials scientist, who opined that the Neptune 2 was defectively designed, unreasonably dangerous, and lacked proper warnings. The materials scientist testified that the user interface was confusing, which could result in the user applying “unsafe vacuum or inappropriate vacuum in the wrong application.” The materials scientist also testified that the warning was confusing and failed to inform the user that, even at its lowest setting, the device should not be connected to a chest tube or closed-wound drain.

The Plaintiff also presented the testimony of a medical device engineer and a former medical officer in the FDA’s Office of Compliance. Taken together, their testimony was that (1) the manufacturer should have sought clearance from the FDA before releasing the Neptune 2; (2) the manufacturer did not undertake a proper risk analysis when it determined that it was not required to obtain separate FDA clearance for it; and (3) the FDA communicated to the manufacturer that the Neptune 2 was an adulterated device which was marketed without FDA clearance.

The manufacturer’s principal defense was that Mr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Force v. Ford Motor Co.
879 So. 2d 103 (District Court of Appeal of Florida, 2004)
Rock v. State
638 So. 2d 933 (Supreme Court of Florida, 1994)
Fabre v. Marin
623 So. 2d 1182 (Supreme Court of Florida, 1993)
Washington v. State
955 So. 2d 1165 (District Court of Appeal of Florida, 2007)
Graham v. State
470 So. 2d 97 (District Court of Appeal of Florida, 1985)
Hooper v. State
476 So. 2d 1253 (Supreme Court of Florida, 1985)
Orosz v. State
389 So. 2d 1199 (District Court of Appeal of Florida, 1980)
Porter v. Rosenberg
650 So. 2d 79 (District Court of Appeal of Florida, 1995)
Middelveen v. Sibson Realty, Inc.
417 So. 2d 275 (District Court of Appeal of Florida, 1982)
Tedder v. Video Electronics, Inc.
491 So. 2d 533 (Supreme Court of Florida, 1986)
Piccott v. State
116 So. 2d 626 (Supreme Court of Florida, 1959)
Jackson v. General Motors Corp.
60 S.W.3d 800 (Tennessee Supreme Court, 2001)
In Re Fosamax Products Liability Litigation
742 F. Supp. 2d 460 (S.D. New York, 2010)
Frank Special v. West Boca Medical Center
160 So. 3d 1251 (Supreme Court of Florida, 2014)
William P. Aubin v. Union Carbide Corporation
177 So. 3d 489 (Supreme Court of Florida, 2015)
McNeil v. State
158 So. 3d 626 (District Court of Appeal of Florida, 2014)
Tillman v. C.R. Bard, Inc.
96 F. Supp. 3d 1307 (M.D. Florida, 2015)
Malota v. State
336 So. 2d 1267 (District Court of Appeal of Florida, 1976)
Porter v. State
388 So. 2d 18 (District Court of Appeal of Florida, 1980)
West v. State
584 So. 2d 1044 (District Court of Appeal of Florida, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
LISA CAVANAUGH, as Personal Representative of the ESTATE OF WILLIAM CAVANAUGH v. STRYKER CORPORATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lisa-cavanaugh-as-personal-representative-of-the-estate-of-william-fladistctapp-2020.